Exicure is a clinical-stage biotechnology company developing immuno-oncology and gene regulatory therapeutics based on our proprietary Spherical Nucleic Acid, or SNA, technology. SNAs are nanoscale constructs consisting of densely packed, synthetic nucleic acid sequences, which are radially arranged in three dimensions. We believe that the design of our SNAs gives rise to distinct advantages over other nucleic acid therapeutics which may enable increased efficacy, improved safety, and less frequent dosing, in a variety of therapeutic indications. At Feb. 29, 2020 we had approx. $107.7 million of cash, cash equivalents, and short-term investments which we believe funds the company into 2022
Immuno-oncology: Exicure is completing the Phase 1b stage of its Phase 1b/2 clinical trial of AST-008 and is preparing to begin in Q2 2020 the Phase 2 stage of dose expansion for intratumoral AST-008 in combination with checkpoint inhibitors in patients with advanced or metastatic Merkel cell carcinoma or cutaneous squamous cell carcinoma.
Neurology: Exicure is developing XCUR-FXN, an SNA–based therapeutic candidate, for the treatment of Friedreich’s ataxia (FA). Preclinical research is ongoing and IND-enabling studies for XCUR-FXN are expected in late 2020.
Exicure entered into a collaboration with Allergan Pharmaceuticals International Limited in late 2019 and is now actively engaged in preclinical research and discovery in two clinical programs related to the treatment of hair loss disorders.
US - East North Central
100MM - 500MM
8045 Lamon Ave.
Skokie, IL 60077
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Top 10 Holders of Exicure, Inc.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by